Shares of Axsome Therapeutics AXSM were up 22.8% on Dec. 31, after it announced that the FDA had accepted the supplemental ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

FDA grants priority review to Axsome's AXS-05 for treating agitation in Alzheimer's disease with a PDUFA date of April 30, 2026.

Axsome Therapeutics (AXSM) announced on Wednesday that the U.S. FDA has granted priority review for its marketing application ...

"We need to find ways to engage frontline staff in the delivery of nonpharmaceutical interventions, including early preferred music, to achieve the goal of safe and effective management of ...

WASHINGTON, Nov. 12, 2025 /PRNewswire/ -- Nearly half (49%) of those caring for someone experiencing agitation symptoms as part of their Alzheimer's dementia reveal that the agitation symptoms are ...

A new systematic review included 37 studies that were focused on exploring the neuropathology of the hyperactive and psychotic symptoms of dementia. Symptoms of dementia were found to overlap with ...

In an interview, company executives said each treatment use they are studying for Cobenfy has multibillion-dollar potential, including Alzheimer's disease psychosis, Alzheimer's agitation and ...

NEW HAVEN, Conn., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience ...

Lamia Scott and her young son moved into her mother's home after she was diagnosed with Alzheimer's. The third grader frequently helps keep his grandmother, 75, calm during her periods of agitation.

What is separation anxiety in individuals with Alzheimer's or dementia and some tips and strategies to manage it? Reluctance and fear of being separated from the individual's primary caregiver, or ...